Otovaksin sebagai terapi alternatif infeksi Mycobacterium tuberculosis pada Tikus Putih (Rattus norvegicus)
Authors
-
Praseno Praseno
-
Nurrokhman Nurrokhman
-
Istiana Fiatiningsih
Keywords:
M. tuberculosis, autogenous vaccine, Rattus norvegicus, alternative medicineAbstract
Tuberculosis (TB) is still an important public health problem, especially in developing countries such as Indonesia. Efforts have been made to overcome the problem, however, number of cases is still high. This is due to various factors which might affect the development of the disease. Increasing number of resistant strains against antimycobacterial drugs is one of the major factors. Therefore, alternative method to control TB is needed.
The aim of this study was to evaluate the effectiveness of autogenous vaccine on healing process of infection caused by Mycobacterium tuberculosis in rats. Eighteen Wistar rats (Rattus norvegicus) were infected with 109 colony forming unit of M. tuberculosis subcutaneously. One week after infection, the rats were divided randomly into 2 groups, first group were treated with autogenous vaccine and the other were left untreated (control group). Autogenous vaccine was given subcutaneously with the dose of 108 cfu/0,1 ml every 7 days 3 times. Subcutaneous nodules were evaluated every 3 days and weight gain was evaluated 3 times. Laboratory examinations were done, including acid fast bacilli stain, histopatological feature and serologic test.
The result showed that recovery of subcutaneous nodules in autovaccine treated group of rats was faster than that of untreated control group. Acid fast bacilli staining showed that the number of micobacteria found in the lung, liver, spleen and kidney of autovaccine treated group were much lower than those found in the control group. Histopathology features showed that lymphocytes infiltration in the lung and other organs was heavier in the control group than that of treated group. In conclusion, animal study on rats showed that autogenous vaccine had effective therapeutic effect on healing process for M. tuberculosis infection.
References
lsagaff JH, Sandika W (editor). 1995. Sistem Pernapasan: Tuberkulosis. Buku Ajar Patologi II. Penerbit Buku Kdokteran EGC. Jakarta.
Andriasari DS, Sutoyo DSK, Ikhsan M, Jusuf A, Mangunnegoro H, Ariawan I, Mulyati D 2000. Peran Uji Serologis ELISA Kp 90 M. tuberculosis terhadap IgA dalam Diagnosis dan Evaluasi Respon Pengobatan TB Paru di RSUP Persahabatan. Jurnal Respirologi Indonesia.; 20(4):138-144
Boyd RF 1995. Basic Medical Microbiology. 5th Edition. Little, Brown, and Company (Inc). USA.
Braunwald 1999 Horrison’s Prinsiples of Internal Medicine. 14th Edition. Vol. 1. The Mc Graw Hill Company, Inc.
Fitriyati Y 1998. Pengaruh Pengobatan terhadap Peningkatan Berat Badan pada Penderita Tuberkulosis Anak di RS Dr Sardjito. Laporan Skripsi FK-UGM.
Handayani S 2002. Respon Imunitas Seluler pada Infeksi Tuberkulosis Paru. Cermin Dunia Kedokteran.; 137:33-6
Kabat 2000. Imunopatogenesis Tuberkulosis Milier. Jurnal Respirologi Indonesia.;20(4):161-6
Lennet EH, Ballos A, Hausler WJ, Shadomi HJ 1980. Manual of Clinical Microbiology. 2nd ed. Washington.
Rintiswati N, Praseno, Saleh S 1997. Pemeriksaan Serologik Menggunakan Antigen Lipoarabinomannan untuk Diagnosis TB Paru. Berkala Ilmu Kedokteran.; 29(3):114-8
Setyawan S 1998. Penyakit Infeksi: Tuberkulosis. Patologi. Bagian Patologi Anatomi FK UI.
Sarah H 1998. WHO. Zona Panas Tuberkulosis. Medika.; 1:68
Subowo 1993. Imunoterapi. Imunologi Klinik. Penerbit Angkasa Bandung.
Sumanto S 2004. Deteksi M. Tuberculosis yang Resisten Obat Menggunakan Metode Molekuler. Majalah Kedokteran Atmajaya, 3(2):117.
Tanjung A, Puteh AG 1997. Masalah Resistensi Kuman Tuber-kulosis Paru Beberapa Hal yang Perlu Mendapat Perhatian. Berkala Ilmu Kedokteran.;20(2):123-9
Tulak A 1997. Peranan Ofloksasin pada Pengobatan Multi Drug Resistant TBC (MDR-TB). Jurnal Respirologi Indonesia.;17(1):59-63
WHO 1974. WHO Expert Committee on Tuberculosis. Ninth Report. Geneva.
WHO 2004. Global Project on Antituberculosis Drug Resistance Surveillance-DRS. Annual Report No. 3. WHO. Geneva
